🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

56 results for “alum” Clear

  1. -, Placebo to ianalumab 150 mg/1 mL concentrate for solution for infusion, -, ENTECAVIR , -, ELTROMBOPAG, -, ELTROMBOPAG, ELTROMBOPAG, VAY736, -, ELTROMBOPAG

    Novartis Pharmaceuticals

    Primary immune thrombocytopenia (ITP)

    phase 3 small molecule active

    1 trial

  2. AVELUMAB, DOSTARLIMAB, ATEZOLIZUMAB, AVELUMAB, CEMIPLIMAB, DOSTARLIMAB, NIVOLUMAB, PEMBROLIZUMAB, NIVOLUMAB, DURVALUMAB, CEMIPLIMAB, ATEZOLIZUMAB, PEMBROLIZUMAB, DURVALUMAB

    Ningbo Cancer Hospital

    Only patients with oncologic locally advanced or metastatic tumour (lung cancer, renal cell cancer (except IMDC favorable-risk treated Tyrosine Kinase Inhibitor [TKI] / immunotherapy [IO] combination), head and neck cancer, urothelial carcinoma, triple negative breast cancer, Merkel cancer, melanoma, hepatocellular carcinoma, colorectal carcinoma with microsatellite instability [MSI], esophageal squamous cell carcinoma, endometrial carcinoma, or cervical cancer, gastric/gastro-esophageal junction/esophageal adenocarcinoma, basal cell carcinoma or squamous skin carcinoma) in partial or complete response (except for melanoma, only patients in partial response) after 6 months of standard IO treatment (monotherapy or previously in combination with other immunotherapy (ipilimumab) or chemotherapy or continuous combination with pemetrexed or bevacizumab or TKI).

    phase 3 small molecule active

    1 trial

  3. BNT327 50 mg ml, DURVALUMAB, BNT327 20 mg ml

    Bristol-Myers Squibb Australia Pty Ltd

    Unresectable Stage III non-small cell lung cancer without progression

    phase 3 small molecule active

    1 trial

  4. DURVALUMAB, IMFINZI 50 mg/mL concentrate for solution for infusion., CISPLATIN, ETOPOSIDE, Olaparib, CARBOPLATIN, MK-7339, Olaparib Placebo, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Olaparib, PEMETREXED, PACLITAXEL

    Merck Sharp and Dohme

    Non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  5. DURVALUMAB, MYCOPHENOLIC ACID , Padcev 20 mg powder for concentrate for solution for infusion, TREMELIMUMAB, Padcev 30 mg powder for concentrate for solution for infusion, INFLIXIMAB

    AstraZeneca AB

    Bladder Cancer

    phase 3 small molecule active

    1 trial

  6. DURVALUMAB, Savolitinib, MYCOPHENOLATE MOFETIL, Sutent 12.5 mg hard capsules, Sutent 25 mg hard capsules, Sutent 12.5 mg hard capsules, INFLIXIMAB, Sutent 25 mg hard capsules

    AstraZeneca AB

    MET-driven, unresectable and locally advanced or metastatic Papillary Renal Cell Carcinoma

    phase 3 small molecule active

    1 trial

  7. Dazodalibep, The placebo is formulated as sterile liquid intended for intravenous infusion following dilution in normal saline. The nominal volume in each vial is 5.0 mL. The placebo is aseptically filled into 6R glass vials, stoppered with a Flurotec-coated elastomeric stopper, and sealed with an aluminum overseal.

    Elan Pharma International

    Sjögren’s Syndrome With Moderate-toSevere Symptom State

    phase 3 small molecule active

    1 trial

  8. Dazodalibep, The placebo is formulated as sterile liquid intended for intravenous infusion following dilution in normal saline. The placebo is aseptically filled into 6R glass vials( the nominal volume in each vial is 5.0 mL) and 20R glass vials (the nominal volume in each vial is 15.0 mL) , stoppered with a Flurotec-coated elastomeric stopper, and sealed with an aluminum overseal.

    Elan Pharma International

    Sjögren’s Syndrome With Moderate-to-severe Systemic Disease Activity

    phase 3 small molecule active

    1 trial

  9. Durvalumab

    AstraZeneca

    Muscle Invasive Bladder Cancer

    phase 3 small molecule active

    1 trial

  10. Durvalumab

    AstraZeneca

    Locally Advanced Cervical Cancer

    phase 3 mab completed

    1 trial

  11. Durvalumab

    AstraZeneca

    Non Small Cell Lung Cancer NSCLC

    phase 3 small molecule active

    1 trial

  12. Durvalumab

    Arcus Biosciences

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  13. Durvalumab

    AstraZeneca

    Carcinoma, Non-Small-Cell Lung

    phase 3 small molecule active

    1 trial

  14. Durvalumab

    AstraZeneca

    Cancer

    phase 3 small molecule active

    1 trial

  15. Durvalumab

    AstraZeneca

    Advanced Hepatocellular Carcinoma

    phase 3 small molecule active

    1 trial

  16. Durvalumab

    AstraZeneca

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    2 trials

  17. Durvalumab

    AstraZeneca

    Hepatocellular Carcinoma

    phase 3 small molecule active

    2 trials

  18. Durvalumab + SoC chemotherapy

    AstraZeneca

    Carcinoma, Non-Small-Cell Lung

    phase 3 small molecule completed

    1 trial

  19. ELECTROLYTES , DURVALUMAB, VASOPRESSIN (ARGIPRESSIN) , PREDNISOLONE , INFLIXIMAB, MYCOPHENOLATE MOFETIL, PARACETAMOL , Tarlatamab, Tarlatamab, TOCILIZUMAB, ETOPOSIDE, DEXAMETHASONE, SILTUXIMAB, CARBOPLATIN, CISPLATIN

    Amgen

    Extensive stage small cell lung cancer (ES-SCLC)

    phase 3 small molecule active

    1 trial

  20. GEMCITABINE, GEMCITABINE, INFLIXIMAB, DURVALUMAB, MYCOPHENOLATE MOFETIL, CISPLATIN

    AstraZeneca AB

    Patients with histologically or cytologically documented muscle-invasive transitional cell carcinoma (TCC) of the bladder

    phase 3 small molecule active

    1 trial

  21. IMFINZI 50 mg/mL concentrate for solution for infusion., DURVALUMAB, MYCOPHENOLATE MOFETIL, Placebo, OncoTICE® powder for instillation fluid for intravesical use containing 2-8 x 108 CFU Tice BCG., INFLIXIMAB

    AstraZeneca AB

    Non-muscle invasive bladder cancer

    phase 3 small molecule active

    1 trial

  22. Ianalumab

    Novartis Pharmaceuticals

    Primary Immune Thrombocytopenia (ITP)

    phase 3 mab active

    1 trial

  23. Ianalumab

    Novartis Pharmaceuticals

    Primary Immune Thrombocytopenia

    phase 3 mab active

    2 trials

  24. MEDI4736 (Durvalumab)

    AstraZeneca

    Non-Small-Cell Lung Carcinoma NSCLC

    phase 3 mab active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources